58,721 results match your criteria Lung Metastases


Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.

Eur Urol Oncol 2019 Mar 24;2(2):141-149. Epub 2018 Sep 24.

Department of Urology, University of Rennes, Rennes, France.

Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy.

Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process.

Evidence Acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.08.028DOI Listing

Primary vaginal adenocarcinoma of intestinal type or occult metastatic colon cancer: a diagnostic dilemma from a vaginal skin tag.

Int J Womens Health 2019 1;11:223-228. Epub 2019 Apr 1.

Department of Gynaecological Oncology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK,

The presentation of a new vaginal lesion could represent a variety of diagnoses from benign warts to more sinister primary malignancies. Rarely, a new lesion could represent a metastatic deposit from a malignancy elsewhere in the body. Colonic carcinomas are the third most common malignancy, frequently metastasising to the liver and lung. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S142002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448537PMC

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.

Br J Cancer 2019 Apr 24. Epub 2019 Apr 24.

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Background: OncoBEAM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA.

Methods: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0457-yDOI Listing
April 2019
1 Read

Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study.

Cancer Epidemiol Biomarkers Prev 2019 Apr 23. Epub 2019 Apr 23.

Deutsches Krebsforschungszentrum (DKFZ)

Background: While enhanced platelet activation and a procoagulant state may drive lung cancer progression and metastases, less is known about their role in earlier phases of cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risk of lung cancer in the prospective EPIC-Heidelberg Study using a case-cohort design.

Methods: Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n=2,480) and incident cases of lung cancer (n=190). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-1285DOI Listing

[A Retrospective Study of 42 Lung Cancer Patients with Pancreatic Metastases].

Zhongguo Fei Ai Za Zhi 2019 Apr;22(4):228-232

Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.

Background: A number of patients with lung cancer have distant metastases at the time of diagnosis. The most common sites for metastases are liver, brain, etc. However pancreatic metastasis is relatively rare, with an insidious onset and poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.05DOI Listing

[Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].

Zhonghua Zhong Liu Za Zhi 2019 Apr;41(4):309-314

Department of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.

To compare the clinical efficacy and drug safety between oral apatinib combined with conventional chemotherapy and conventional chemotherapy alone for the treatment of osteosarcoma and soft tissue sarcoma patients with pulmonary metastasis. Thirty-three osteosarcoma and soft tissue sarcoma patients with pulmonary metastasis who were treated in the Department of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University from January 2015 to December 2017 were enrolled in this study. Patients with osteosarcoma received methotrexate, adriamycin (ADM), cisplatin (CDDP), ifosfamide (IFO) sequential regimen; patients with soft tissue sarcoma were treated with IFO and ADM regimen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.04.012DOI Listing

The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases.

PLoS One 2019 23;14(4):e0215861. Epub 2019 Apr 23.

Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Background: There has been significant uncertainty in the selection of candidates for cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC). This report investigates the influence of site-specific metastases (bone, brain, liver, and lung) on the survival benefit of CN.

Methods: Within the Surveillance, Epidemiology and End Results database (2010-2014), 1113 mRCC patients treated with CN (n = 618) or no surgery (NS, n = 495) met the selection criteria. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215861PLOS
April 2019
1 Read

Pelvic reconstruction following resection of tumour involving the whole ilium and acetabulum.

J Bone Oncol 2019 Jun 27;16:100234. Epub 2019 Mar 27.

Bone and Soft Tissue Tumour Centre, People's Hospital of Beijing University, Beijing 100044, China.

Background: Functional reconstruction following resection of pelvic tumours with the ileum and the acetabulum involvement is challenging and demanding. The aim of this study was to evaluate the results of these patients receiving pelvic reconstruction with a femoral head autograft plus a hemipelvic prosthesis.

Methods: Eighteen patients receiving pelvic reconstruction with a femoral head autograft plus a hemipelvic prosthesis following resection of pelvic tumours involving the whole ileum and the acetabulum were included in this study from April 2006 to June 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbo.2019.100234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460299PMC

Disparities in the Use of Single-fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases From Non-small Cell Lung Cancer.

Cureus 2019 Feb 7;11(2):e4031. Epub 2019 Feb 7.

Radiation Oncology, Henry Ford Hospital, Detroit, USA.

Purpose: Radiation treatment patterns in patients with brain metastases from non-small cell lung cancer (NSCLC) have not been well elucidated. The National Cancer Database (NCDB) was used to evaluate trends in the use of whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) for brain metastasis from NSCLC.

Methods: This NCDB study included patients > 18 years old with metastatic NSCLC treated with single-fraction SRS or WBRT between 2004 and 2014. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/17567-disparities-in-the-use
Publisher Site
http://dx.doi.org/10.7759/cureus.4031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456282PMC
February 2019
1 Read

Gallbladder Metastases: A Report of Two Cases.

Case Rep Oncol 2019 Jan-Apr;12(1):235-240. Epub 2019 Mar 19.

Virginia Tech Carilion School of Medicine, Division of Gastroenterology and Hepatology, Roanoke, Virginia, USA.

Introduction: Metastasis to the gallbladder is not common and usually manifests an advanced stage of malignancy. Herein, we report a case of triple negative high grade invasive ductal carcinoma of breast with a metastatic lesion to the gallbladder.

Case Presentation: The patient is a 52-year-old female diagnosed with invasive ductal carcinoma treated with mastectomy and chemotherapy. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497818
Publisher Site
http://dx.doi.org/10.1159/000497818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465751PMC
March 2019
1 Read

Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.

Nat Biomed Eng 2018 Jun 23;2(6):443-452. Epub 2018 Apr 23.

Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Metastatic disease remains the primary cause of mortality in cancer patients. Yet the number of available in vitro models to study metastasis is limited by challenges in the recapitulation of the metastatic microenvironment in vitro, and by difficulties in maintaining colonized-tissue specificity in the expansion and maintenance of metastatic cells. Here, we show that decellularized scaffolds that retain tissue-specific extracellular-matrix components and bound signalling molecules enable, when seeded with colorectal cancer cells, the spontaneous formation of three-dimensional cell colonies that histologically, molecularly and phenotypically resemble in vivo metastases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41551-018-0231-0
Publisher Site
http://dx.doi.org/10.1038/s41551-018-0231-0DOI Listing
June 2018
1 Read

Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.

Clin Cancer Res 2019 Apr 22. Epub 2019 Apr 22.

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Tumors are continuously evolving biological systems, and medical imaging is uniquely positioned to monitor changes throughout treatment. Although qualitatively tracking lesions over space and time may be trivial, the development of clinically relevant, automated radiomics methods that incorporate serial imaging data is far more challenging. In this study, we evaluated deep learning networks for predicting clinical outcomes through analyzing time series CT images of patients with locally advanced non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-2495DOI Listing
April 2019
1 Read

Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination.

Cancers (Basel) 2019 Apr 19;11(4). Epub 2019 Apr 19.

INSERM U1053 Bordeaux Research in Translational Oncology, University of Bordeaux, 33076 Bordeaux CEDEX, France.

Gastric cancer is the third leading cause of cancer mortality worldwide. Cancer stem cells (CSC) are at the origin of tumor initiation, chemoresistance, and the formation of metastases. However, there is a lack of mouse models enabling the study of the metastatic process in gastric adenocarcinoma (GC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040560DOI Listing

An occult urothelial carcinoma with wide multiorgan metastases and its genetic alteration profiling: Case report and literature review.

Medicine (Baltimore) 2019 Apr;98(16):e15245

Department of Comprehensive Internal Medicine, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning.

Rationale: Urothelial carcinoma, also named transitional cell carcinoma, is the most frequent occurring malignancy in the urinary system. It mainly invades the surrounding tissues and metastasizes to distant organs in later stages.

Patient Concerns: Here, we presented an unusual case of occult urothelial carcinoma primarily manifested as a multiorgan metastatic cancer in a 59-year-old man. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015245DOI Listing

Poorly differentiated adenocarcinoma of an unknown primary with a thyroid tumour and an aggressive course: thyroid or lung carcinoma?

Oxf Med Case Reports 2019 Apr 16;2019(4):omy129. Epub 2019 Apr 16.

Division of Internal Medicine, Department of Internal Medicine, Chitose City Hospital, Hokkaido 066-8550, Japan.

Cancers of unknown primary (CUPs) are challenging for physicians to diagnose and treat. Metastases to the thyroid gland are rare, representing less than 1% of all thyroid malignancies. Here, we report a case of a 69-year-old Asian man who had both thyroid gland and lymph node enlargement in the neck and shoulders but no nodules/tumours in the lung field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omy129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467094PMC

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature.

Mol Clin Oncol 2019 May 5;10(5):506-510. Epub 2019 Mar 5.

Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350-1298, Japan.

A 66-year-old Japanese male patient was referred to Saitama Medical University International Medical Center for treatment of bladder cancer (clinical stage T2 or higher without metastasis), and underwent radical cystectomy with pelvic lymphadenectomy. The histopathological diagnosis was high-grade urothelial carcinoma (pathological stage T2bN2, ly1, v0) and 2 cycles of adjuvant systemic chemotherapy (gemcitabine plus cisplatin) were administered. At 15 months after the operation, mediastinal and lung hilar lymph nodes and multiple bone metastases were identified on computed tomography imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2019.1820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466998PMC

[Clear cell kidney carcinoma revealed by cutaneous and sinus metastases: about a case and literature review].

Pan Afr Med J 2018 1;31:66. Epub 2018 Oct 1.

Service d'Oncologie Médicale, CHU de Brazzaville, République du Congo.

Kidney cancer is the third most frequent urologic cancer. Metastases usually occur in the lung, the bone and the liver. We here report a clinical case of cutaneous and sinus metastases revealing kidney cancer in a 70 year old man. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.31.66.16721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457736PMC
October 2018

A PET study in healthy subjects of brain exposure of C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.

J Cereb Blood Flow Metab 2019 Apr 20:271678X19843776. Epub 2019 Apr 20.

1 Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of this PET study was therefore to determine brain distribution and exposure of C-labelled osimertinib administered intravenously in subjects with an intact blood-brain barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0271678X19843776DOI Listing

Multiple bilateral choroidal metastases in stage IV lung cancer.

Authors:
Cari L Nealon

Clin Exp Optom 2019 Apr 21. Epub 2019 Apr 21.

Optometry Section, Louis Stokes Cleveland Veterans Affairs Medical Centre, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cxo.12907DOI Listing

Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

J Thorac Oncol 2019 Apr 16. Epub 2019 Apr 16.

Guangdong Lung Cancer Institute; Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences; Guangzhou; China.

In 2018 research in the field of advanced non-small cell lung cancers (NSCLC) led to an expanded reach and impact of immune-checkpoint inhibitors (ICIs) as part of frontline treatment strategy, regardless of histology subtype, while ICI use was extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard care after progression on ICIs. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression on ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193028
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.03.022DOI Listing
April 2019
6 Reads

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.

PLoS One 2019 19;14(4):e0214599. Epub 2019 Apr 19.

Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan.

Purpose: Oligometastasis is a state in which cancer patients have a limited number of metastatic tumors; patients with oligometastases survive longer than those with polymetastases. Extensive disease (ED)-small cell lung cancer (SCLC) is considered a systemic disease and a poor survival. This study investigated whether the concept of oligometastases is prognostic factor also applicable to patients with ED-SCLC. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214599PLOS
April 2019
2 Reads

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma.

J Clin Med 2019 Apr 17;8(4). Epub 2019 Apr 17.

Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.

Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung.

Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2077-0383/8/4/529
Publisher Site
http://dx.doi.org/10.3390/jcm8040529DOI Listing
April 2019
1 Read

An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.

Bosn J Basic Med Sci 2019 Apr 18. Epub 2019 Apr 18.

Nuclear Medicine Department, Firat University Medical Faculty, Elazığ, Turkey.

In some non-small cell lung cancer (NSCLC) patients, lipid-poor adrenal adenomas cannot be adequately differentiated from metastases using imaging methods. Invasive diagnostic procedures also have a low negative predictive value (NPV) in such cases. The current study aims to establish a specific and clinically practical metabolic parameter for lipid-poor adrenal lesions (ALs) in NSCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17305/bjbms.2019.3837DOI Listing
April 2019
1 Read

Comparison of pulmonary metastasectomy and stereotactic body radiation therapy for the treatment of lung metastases.

J Thorac Dis 2019 Mar;11(Suppl 3):S280-S282

Department of Thoracic Surgery, IRCCS European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/26804/20211
Publisher Site
http://dx.doi.org/10.21037/jtd.2019.01.72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424761PMC
March 2019
1 Read

Which patients with ischaemic priapism require further investigation for malignancy?

Int J Impot Res 2019 Apr 17. Epub 2019 Apr 17.

Andrology Department, University College, 47 Wimpole St, London, W1G 8PH, UK.

Ischaemic priapism (IP) is characterised by a persistent, painful penile erection lasting for >4 h. Many causes of IP have been identified including haematological dyscrasias (particularly, sickle cell disease), drugs and rarely malignancy. There are also a large proportion of men, in which no aetiology is identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41443-019-0141-zDOI Listing
April 2019
1 Read

Defining patterns of care in the management of patients with brain metastases in a large oncology centre: A single-centre retrospective audit of 236 cases.

Eur J Cancer Care (Engl) 2019 Apr 16:e13059. Epub 2019 Apr 16.

Department of Oncology and Radiotherapy, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Aims: The role of selected treatments for brain metastases (BM) is well documented; however, the prevalence of these is not. We report on the patterns of care in the management of BM in a large oncology centre.

Materials And Methods: We retrospectively audited 236 cases of newly diagnosed BM from January 2016 to December 2017 by looking at 2 years of radiology reports and gathered data on primary site, survival, treatment received, palliative care input and brain metastases-related admissions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ecc.13059DOI Listing
April 2019
1 Read

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.

BMC Cancer 2019 Apr 16;19(1):360. Epub 2019 Apr 16.

Department of Urology, West China Hospital, Sichuan University, Chengdu, People's Republic of China, 610041.

Background: In clinical practice, the detection of biomarkers is mostly based on primary tumors for its convenience in acquisition. However, immune checkpoints may express differently between primary and metastatic tumor. Therefore, we aimed to compare the differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastatic sites of renal cell carcinoma (RCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5578-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469103PMC
April 2019
1 Read

Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome.

BMC Cancer 2019 Apr 16;19(1):362. Epub 2019 Apr 16.

Department of Gastroenterology and Endocrinology, University Hospital Marburg, Baldinger Strasse, 35043, Marburg, Germany.

Background: Brain metastases (BM) are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NET) of the gastroenteropancreatic (GEP) or bronchopulmonary system. However, symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.

Methods: We retrospectively analyzed 51 patients with GEP-NEN and bronchopulmonary NEN excluding small cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5559-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469052PMC
April 2019
1 Read

Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors.

Thorac Cardiovasc Surg 2019 Apr 16. Epub 2019 Apr 16.

Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

Background:  Bilateral lung neoplasms are becoming more common, but distinguishing two primary lung cancers from metastatic disease can be difficult and only long-term follow-up after treatment can disclose the real behavior of the disease.The present study aimed to identify the appropriate candidates for bilateral surgical resections from the perspective of short-term postoperative complications and long-term outcomes.

Methods:  Two hundred and fifteen consecutive patients undergoing bilateral pulmonary resection for lung cancers over a 20-year period were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1685472DOI Listing
April 2019
1 Read

Survival and prognostic factors in surgically treated brain metastases.

J Neurooncol 2019 Apr 16. Epub 2019 Apr 16.

Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, 60 Fenwood Rd., 4th Floor, Boston, MA, 02115, USA.

Purpose: While surgery and radiation remain the mainstays of therapy for all patients with brain metastases (BM), the management is moving to a more individualized approach based on the underlying tumor. We sought to identify prognostic factors of both intracranial progression (IC-PFS) and overall survival (OS) in a surgical cohort.

Methods: We retrospectively reviewed the records of 1015 patients treated surgically for BM at Brigham and Women's Hospital (2007-2017). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-019-03171-6
Publisher Site
http://dx.doi.org/10.1007/s11060-019-03171-6DOI Listing
April 2019
2 Reads

Increased Risk of Lung Metastases in Patients with Giant Cell Bone Tumors: A Systematic Review.

Authors:
Josef Yayan

Adv Exp Med Biol 2019 Apr 16. Epub 2019 Apr 16.

Department of Internal Medicine, Division of Pulmonary, Allergy and Sleep Medicine, HELIOS Clinic Wuppertal, Witten/Herdecke University, Witten, Germany.

Giant cell tumors of the bone are rare, usually benign, tumors consisting of large, multinucleated bone cells. Remarkably, these tumors are characterized by aggressive growth. They tend to recur frequently and, in rare cases, metastasize to the lungs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/5584_2019_372DOI Listing
April 2019
1 Read

Long-term survival after adrenal metastasectomy from colorectal cancer: a report of two cases.

Surg Case Rep 2019 Apr 15;5(1):61. Epub 2019 Apr 15.

Department of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.

Background: Solitary adrenal metastasis from colorectal cancer is rare. Adrenal metastasis is usually detected with synchronous multiple metastases in other organs and is, therefore, considered to be unsuitable for surgical resection. The long-term outcomes of patients with solitary adrenal metastasectomy from colorectal cancer have been reported; however, the survival advantage has not been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0611-zDOI Listing
April 2019
4 Reads

Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors.

Front Oncol 2019 29;9:205. Epub 2019 Mar 29.

Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

Significantly better local control is achieved with combination of whole brain radiotherapy and stereotactic radiosurgery in the treatment of multiple brain metastases. However, no survival benefit was reported from this advantage in local control. The objective of this study was to review the available evidence whether better local control achieved with whole brain radiotherapy plus stereotactic radiosurgery leads to any benefit in survival in patients with favorable prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449627PMC
March 2019
1 Read

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Front Oncol 2019 29;9:199. Epub 2019 Mar 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

There is increasing use of immune checkpoint blockade (ICB) across multiple cancer types, including in patients at risk for vertebral metastases and cord compression. These patients are often treated with palliative radiotherapy (PRT); however, data evaluating the combination of PRT and ICB in patients with vertebral metastases is limited. Furthermore, patients with cord compression are generally excluded from prospective clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450051PMC
March 2019
2 Reads

Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases.

Front Oncol 2019 28;9:184. Epub 2019 Mar 28.

Academic Department of Radiation Oncology, Centre Oscar Lambret, University Lille II, Lille, France.

The aim of this study was to assess, in a large series, the efficacy and tolerance of post-operative adjuvant hypofractionated stereotactic radiation therapy (HFSRT) for brain metastases (BMs). Between July 2012 and January 2017, 160 patients from 2 centers were operated for BM and treated by HFSRT. Patients had between 1 and 3 BMs, no brainstem lesions or carcinomatous meningitis. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2019.00184/
Publisher Site
http://dx.doi.org/10.3389/fonc.2019.00184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448411PMC
March 2019
2 Reads

Tspan8 is expressed in breast cancer and regulates E-cadherin / catenin signalling and metastasis accompanied by increased circulating extracellular vesicles.

J Pathol 2019 Apr 14. Epub 2019 Apr 14.

Institute for Infection Prevention and Hospital Epidemiology; Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.

Tspan8 exhibits a functional role in many cancer types including pancreatic, colorectal, oesophagus carcinoma and melanoma. We present a first study on the expression and function of Tspan8 in breast cancer. Tspan8 protein was present in the majority of human primary breast cancer lesions and metastases in the brain, bone, lung, and liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5281DOI Listing
April 2019
2 Reads

Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases.

J Neurooncol 2019 Apr 13. Epub 2019 Apr 13.

Department of Neurological Surgery, University of California - Davis, 4800 Y Street, Suite 3740, Sacramento, CA, 95817, USA.

Background: Stereotactic radiosurgery (SRS) can enhance immune activation and improve disease control through stimulation of anti-tumor immunity. However, patients with cancer receiving chemotherapy are often immunosuppressed, which may impact the efficacy of SRS. Here we investigate the relationship between systemic lymphopenia and response to SRS in patients with brain-metastatic lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03169-0DOI Listing
April 2019
2 Reads

"Melting Lymph Node Sign": The Endobronchial Ultrasound Pattern of Cystic Mediastinal Nodal Metastases.

Ann Thorac Surg 2019 Apr 11. Epub 2019 Apr 11.

Pathology Unit, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.

Cystic change in metastatic lymph nodes occurs in certain types of tumors (i.e., papillary thyroid carcinoma, squamous cell carcinoma of the Waldeyer's ring) and it is usually observed in the head and neck region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2019.03.038DOI Listing
April 2019
1 Read

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Lancet Respir Med 2019 Apr 10. Epub 2019 Apr 10.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address:

Background: Anaplastic lymphoma kinase-positive (ALK-positive) disease occurs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence reported in Asian patients. This study is the first phase 3 randomised trial recruiting only Asian patients to compare alectinib with crizotinib as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alectinib twice per day. This study assessed consistency of the progression-free survival benefit with the global phase 3 ALEX study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30053-0DOI Listing
April 2019
1 Read

Metastases to the breast, an uncommon diagnosis: what do radiologists need to know?

Radiologia 2019 Apr 10. Epub 2019 Apr 10.

Servicio de Anatomía Patológica, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Objective: To analyze the imaging characteristics of histologically diagnosed metastases to the breast.

Material And Methods: We selected patients histologically diagnosed with metastases to the breast in our diagnostic and interventional breast imaging unit between March 2010 and September 2018.

Results: A total of 9 patients (all women; mean age, 60 y; age range, 28-89 y) were diagnosed with metastases to the breast. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00338338193003
Publisher Site
http://dx.doi.org/10.1016/j.rx.2019.02.004DOI Listing
April 2019
2 Reads

Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.

Biomed Pharmacother 2019 Apr 10;114:108864. Epub 2019 Apr 10.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China. Electronic address:

Hepatocellular carcinoma (HCC) prognosis remains dismal due to postsurgical recurrence and distant metastasis. Therefore, novel prognostic biomarkers and therapeutic targets for HCC therapy are urgently needed to improve the survival of liver cancer patients. Our evidence suggests that SLC46A3 (the gene solute carrier family 46 (sodium phosphate), member 3) is a member of the SLC46 family and has a potential role in the progression and treatment of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108864DOI Listing
April 2019
1 Read
2.023 Impact Factor

Biochemical pathways mediated by KLK6 protease in breast cancer.

Mol Oncol 2019 Apr 13. Epub 2019 Apr 13.

Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, 265 04, Greece.

KLK6 is a serine protease normally expressed in mammary tissue, and aberrantly regulated in breast cancer. At physiological levels, KLK6 functions as a suppressor of breast cancer, while its aberrant overexpression (>50-fold higher than normal) is characteristic of a subset of breast cancers and has been linked to accelerated growth of primary breast tumors in SCID mice (Pampalakis et al. Cancer Res 2009). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12493DOI Listing
April 2019
1 Read

Radiological findings and surgical outcomes of pulmonary metastases originating from biliary tract carcinoma.

Gen Thorac Cardiovasc Surg 2019 Apr 12. Epub 2019 Apr 12.

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Purpose: Metastasis to the lungs arising from biliary tract carcinoma (BTC) is extremely rare, and the patient characteristics and prognosis are not well known. We aimed to identify the imaging findings of pulmonary metastases originating from BTC and the eligible indications for surgical treatment.

Methods: Fifteen patients who underwent pulmonary resection for metastases originating from BTC were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11748-019-01122-6DOI Listing
April 2019
1 Read

Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.

Dis Esophagus 2019 Apr 12. Epub 2019 Apr 12.

Department of Gastroenterological Surgery.

Esophagectomy represents the standard treatment strategy for superficial esophageal cancer diagnosed pathologically as submucosal disease (pT1b) following an endoscopic resection (ER). However, chemoradiotherapy (CRT) is expected to become an alternative treatment option. This study retrospectively compared the outcomes of patients who underwent ER of submucosal esophageal squamous cell carcinoma, and who received additional treatment in the form of surgery and CRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/dote/doz023DOI Listing
April 2019
1 Read

Complete and Durable Response to Combined Chemo/Radiation Therapy in Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases.

Diagnostics (Basel) 2019 Apr 11;9(2). Epub 2019 Apr 11.

Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy.

Most non-small-cell lung cancer (NSCLC) patients are likely to develop brain metastases during the course of their illness. Currently, no consensus on NSCLC patients' treatment with brain metastasis has been established. Although whole brain radiotherapy prolongs the median survival time of approximately 4 months, a cisplatin-pemetrexed combination may also represent a potential option in the treatment of asymptomatic NSCLC patients with brain metastases. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2075-4418/9/2/42
Publisher Site
http://dx.doi.org/10.3390/diagnostics9020042DOI Listing
April 2019
2 Reads

Vascular white matter lesions negatively correlate with brain metastases in malignant melanoma-Results from a retrospective comparative analysis.

Clin Neurol Neurosurg 2019 May 19;180:117-121. Epub 2019 Mar 19.

Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Leipzig, Stephanstraße 9 a, 04103, Leipzig, Germany. Electronic address:

Objectives: Brain metastasis (BM) is a major complication of different cancers. There is increasing evidence for influence of vascular factors on BM in patients with non-small cell lung cancer (NSCLC). It is not known if the same is true for other tumors that might rely on different forms of vasculogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2019.03.016DOI Listing
May 2019
1 Read

Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.

Int J Cancer 2019 Apr 11. Epub 2019 Apr 11.

Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University.

Lung metastasis is one of the leading causes of death for triple-negative breast cancer (TNBC). We sought to characterize the genetic alterations underlying TNBC lung metastases by integrating whole-genome sequencing and functional screening. Further, we aimed to develop a metastasis-related gene signature for TNBC patients to improve risk stratification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32329DOI Listing
April 2019
1 Read

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.

Target Oncol 2019 Apr 11. Epub 2019 Apr 11.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Background: Approximately 1-2% of patients with non‒small-cell lung cancer (NSCLC) harbor ROS1 rearrangements. Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC.

Objective: Our objective was to analyze the efficacy and safety of crizotinib treatment in Chinese patients with advanced NSCLC with ROS1 rearrangement in real-world clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00636-6DOI Listing
April 2019
1 Read

Phosphorylated-Akt overexpression is associated with a higher risk of brain metastasis in patients with non-small cell lung cancer.

Biochem Biophys Rep 2019 Jul 25;18:100625. Epub 2019 Mar 25.

Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.

Brain metastasis (BM) of non-small cell lung cancer (NSCLC) is relatively common and has a poor prognosis. Moreover, identifying which patients are more likely to develop BM is challenging. Akt, a serine/threonine-specific protein kinase, can be activated in various tumors, including lung cancer, and may be associated with poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrep.2019.100625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444023PMC
July 2019
1 Read

Aggressive Ciliary Body Adenocarcinoma with Bilateral Lung Metastases: Histological, Molecular, Genetic and Clinical Aspects.

Ocul Oncol Pathol 2019 Feb 7;5(2):79-84. Epub 2018 May 7.

Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Purpose Of The Study: To describe the clinical and histopathological features of an aggressive ciliary body adenocarcinoma with pulmonary metastases and skull base spread.

Procedures And Results: A 45-year-old female patient presented with a post-traumatic phthisical eye that was eviscerated. This showed an unexpected carcinoma (positive for cytokeratins and melanocytic markers), the histological differential diagnosis for which included a primary ciliary body adenocarcinoma or a metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422130PMC
February 2019
1 Read